Renub Research study titled “United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies” provides a comprehensive assessment of the fast–evolving, high–growth Global Molecular Diagnostics Market. This 128 page report with 87 Figures studies the United States Molecular Diagnostics from 4 view points:

• Market and Forecast
• Application Wise Market & Forecast
• Application Wise Test Volume & Forecast
• Company Wise Molecular Diagnostics Sales & Forecast

Table of Contents

1. Executive Summary

2. United States Molecular Diagnostics Market, Test Volume & Forecast (2010 – 2018)
2.1 United States Molecular Diagnostics Market & Forecast
2.2 United States Molecular Diagnostics Test Volume & Forecast

3. United States Molecular Diagnostics Market & Volume Share (2010 – 2018)
3.1 United States Molecular Diagnostics Market Share & Forecast – Application Wise
3.2 United States Molecular Diagnostics Market Share & Forecast – Company Wise
3.3 United States Molecular Diagnostics Test Volume Share & Forecast – Application Wise

4. United States Molecular Diagnostics Market & Forecast – Application Wise
4.1 Oncology Testing Market (2004 – 2018)
4.1.1 Breast Cancer Testing Market (2004 – 2018)
4.1.2 Colorectal Cancer Testing Market (2004 – 2018)
4.1.3 Prostate Cancer Testing Market (2004 – 2018)
4.1.4 Other Cancer Testing Market (2004 – 2018)
4.2 Infectious Disease Testing Market (2010 – 2018)
4.2.1 Virology Testing Market (2007 – 2018)
4.2.2 HPV Testing Market (2004 – 2018)
4.2.3 HAI Testing Market (2010 – 2018)
4.2.4 Critical Care Testing Market (2010 – 2018)
4.3 Genetic Testing Market (2010 – 2018)
4.4 Blood Screening Market (2006 – 2018)
4.5 Food Pathogen Testing Market (2010 – 2018)
4.6 Tissue Typing (HLA) Testing Market (2008 – 2018)

5. United States Molecular Diagnostics Test Volume – Application Wise
5.1 Oncology Test Volume (2004 – 2018)
5.1.1 Breast Cancer Test Volume (2004 – 2018)
5.1.2 Colorectal Cancer Test Volume (2004 – 2018)
5.1.3 Prostate Cancer Test Volume (2004 – 2018)
5.1.4 Other Cancer Test Volume (2004 – 2018)
5.2 Infectious Disease Test Volume (2010 – 2018)
5.2.1 Virology Test Volume (2007 – 2018)
5.2.2 HPV Test Volume (2004 – 2018)
5.2.3 HAI Test Volume (2010 – 2018)
5.2.4 Critical Care Test Volume (2010 – 2018)
5.3 Genetic Testing Test Volume & Forecast (2010 – 2018)
5.4 Blood Screening Test Volume & Forecast (2006 – 2018)
5.5 Food Pathogen Test Volume & Forecast (2010 – 2018)
5.6 HLA Test Volume & Forecast (2008 – 2018)

6. United States Molecular Diagnostics Market –   Company Wise
6.1 Roche – United States Molecular Diagnostic Sales and Forecast
6.2 Abbott Laboratories – United States Molecular Diagnostic Sales and Forecast
6.3 Myriad Genetics – United States Molecular Diagnostic Sales and Forecast
6.4 Biomerieux – United States Molecular Diagnostic Sales and Forecast
6.5 Qiagen – United States Molecular Diagnostic Sales and Forecast
6.6 Hologic Inc. (Acquired Gen–Probe) – United States Molecular Diagnostic Sales and Forecast
6.7 Becton Dickinson – United States Molecular Diagnostic Sales and Forecast
6.8 Siemens – United States Molecular Diagnostic Sales and Forecast
6.9 Cepheid – United States Molecular Diagnostic Sales and Forecast
6.10 Others – United States Molecular Diagnostic Sales and Forecast

7. United States Molecular Diagnostics Market – Driving Factors
7.1 Point A
7.2 Point B
7.3 Point C

8. United States Molecular Diagnostics Market – Challenges
8.1 Point A
8.2 Point B
8.3 Point C

List of Figures

Figure 2–1: United States – Molecular Diagnostics Market (Million US$), 2010 – 2013
Figure 2–2: United States – Forecast for Molecular Diagnostics Market (Million US$), 2014 – 2018
Figure 2–3: United States – Molecular Diagnostics Test Volume (Million), 2010 – 2013
Figure 2–4: United States – Forecast for Molecular Diagnostics Test Volume (Million), 2014 – 2018
Figure 3–1: United States – Molecular Diagnostics Applications Market Share (Percent), 2010 – 2013
Figure 3–2: United States – Forecast for Molecular Diagnostics Applications Market Share (Percent), 2014 – 2018
Figure 3–3: United States – Company Wise Molecular Diagnostics Market Share (Percent), 2010 – 2013
Figure 3–4: United States – Forecast for Company Wise Molecular Diagnostics Market Share (Percent), 2014 – 2018
Figure 3–5: United States – Molecular Diagnostics Applications Test Volume Share (Percent), 2010 – 2013
Figure 3–6: United States – Forecast for Molecular Diagnostics Applications Test Volume Share (Percent), 2014 – 2018
Figure 4–1: United States – Molecular Diagnostic Oncology Testing Market (Million US$), 2004 – 2013
Figure 4–2: United States – Forecast for Molecular Diagnostic Oncology Testing Market (Million US$), 2014 – 2018
Figure 4–3: United States – Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–4: United States – Forecast for Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–5: United States – Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–6: United States – Forecast for Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–7: United States – Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–8: United States – Forecast for Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–9: United States – Other Molecular Diagnostic Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–10: United States – Forecast for Other Molecular Diagnostic Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–11: United States – Infectious Disease Testing Market (Million US$), 2010 – 2013
Figure 4–12: United States – Forecast for Infectious Disease Testing Market (Million US$), 2014 – 2018
Figure 4–13: United States – Virology Testing Market (Million US$), 2007 – 2018
Figure 4–14: United States – Forecast for Virology Testing Market (Million US$), 2014 – 2018
Figure 4–15: United States – HPV Testing Market (Million US$), 2004 – 2013
Figure 4–16: United States – Forecast for HPV Testing Market (Million US$), 2014 – 2018
Figure 4–17: United States – HAI Testing Market (Million US$), 2010 – 2013
Figure 4–18: United States – Forecast for HAI Testing Market (Million US$), 2014 – 2018
Figure 4–19: United States – Critical Care Testing Market (Million US$), 2010 – 2013
Figure 4–20: United States – Forecast for Critical Care Testing Market (Million US$), 2014 – 2018
Figure 4–21: United States – Genetic Testing Market (Million US$), 2010 – 2013
Figure 4–22: United States – Forecast for Genetic Testing Market (Million US$), 2014 – 2018
Figure 4–23: United States – Blood Screening Market (Million US$), 2006 – 2013
Figure 4–24: United States – Forecast for Blood Screening Market (Million US$), 2014 – 2018
Figure 4–25: United States – Food Pathogen Testing Market (Million US$), 2010 – 2013
Figure 4–26: United States – Forecast for Food Pathogen Testing Market (Million US$), 2014 – 2018
Figure 4–27: United States – HLA Testing Market (Million US$), 2008 – 2013
Figure 4–28: United States – Forecast for HLA Testing Market (Million US$), 2014 – 2018
Figure 5–1: United States – Oncology Test Volume (Million), 2004 – 2013
Figure 5–2: United States – Forecast for Oncology Test Volume (Million), 2014 – 2018
Figure 5–3: United States – Breast Cancer Test Volume (Million), 2004 – 2013
Figure 5–4: United States – Forecast for Breast Cancer Test Volume (Million), 2014 – 2018
Figure 5–5: United States – Colorectal Cancer Test Volume (Million), 2004 – 2013
Figure 5–6: United States – Forecast for Colorectal Cancer Test Volume (Million), 2014 – 2018
Figure 5–7: United States – Prostate Cancer Test Volume (Million), 2004 – 2013
Figure 5–8: United States – Forecast for Prostate Cancer Test Volume (Million), 2014 – 2018
Figure 5–9: United States – Other Cancer Test Volume (Million), 2004 – 2013
Figure 5–10: United States – Forecast for Other Cancer Test Volume (Million), 2014 – 2018
Figure 5–11: United States – Infectious Disease Test Volume (Million), 2010 – 2013
Figure 5–12: United States – Forecast for Infectious Disease Test Volume (Million), 2014 – 2018
Figure 5–13: United States – Virology Test Volume (Million), 2007 – 2018
Figure 5–14: United States – Forecast for Virology Test Volume (Million), 2014 – 2018
Figure 5–15: United States – HPV Test Volume (Million), 2004 – 2013
Figure 5–16: United States – Forecast for HPV Test Volume (Million), 2014 – 2018
Figure 5–17: United States – HAI Test Volume (Million), 2010 – 2013
Figure 5–18: United States – Forecast for HAI Test Volume (Million), 2014 – 2018
Figure 5–19: United States – Critical Care Test Volume (Million), 2010 – 2013
Figure 5–20: United States – Forecast for Critical Care Test Volume (Million), 2014 – 2018
Figure 5–21: United States – Genetic Testing Test Volume (Million), 2010 – 2013
Figure 5–22: United States – Forecast for Genetic Testing Test Volume (Million), 2014 – 2018
Figure 5–23: United States – Blood Screening Test Volume (Million), 2006 – 2013
Figure 5–24: United States – Forecast for Blood Screening Test Volume (Million), 2014 – 2018
Figure 5–25: United States – Food Pathogen Test Volume (Million), 2010 – 2013
Figure 5–26: United States – Forecast for Food Pathogen Test Volume (Million), 2014 – 2018
Figure 5–27: United States – HLA Test Volume (Million), 2008 – 2013
Figure 5–28: United States – Forecast for HLA Test Volume (Million), 2014 – 2018
Figure 6–1: Roche – United States Molecular Diagnostic Sales (Million US$), 2008 – 2013
Figure 6–2: Roche – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–3: Abbott Laboratories – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–4: Abbott Laboratories – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–5: Myriad Genetics – United States Molecular Diagnostic Sales (Million US$), 2007 – 2013
Figure 6–6: Myriad Genetics – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–7: Biomerieux – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–8: Biomerieux – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–9: Qiagen – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–10: Qiagen – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–11: Hologic–Gen–Probe – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–12: Hologic–Gen–Probe – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–13: Becton Dickinson – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–14: Becton Dickinson – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–15: Siemens – United States Molecular Diagnostic Sales (Million US$), 2008 – 2013
Figure 6–16: Siemens – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–17: Cepheid – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–18: Cepheid – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–19: Others – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–20: Others – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 7–1: United States – Investment in the Human Genome Project (Billion US$), 2003, 2012